DS-2325a

DB18134InvestigationalGene Therapies

DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.

Code names
DS-2325a

Resolves to

Compound
UNIIS9CR2ZV5Z4

What you can answer from here — as of April 23, 2025

2Clinical trialsPhase, status and sponsor resolved per trial
Sign in

Which companies are running trials of DS-2325a, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In